Inova launches a new anti-inflammatory

Norflex geliNova Pharmaceuticals is proud to launch a new anti-inflammatory gel,1 to add to South Africa’s most prescribed muscle relaxant brand, Norflex.

Norflex Gel, is the first-to-market anti-inflammatory Benzydamine Hydrochloride topical gel in South Africa. It provides patients with a short-term treatment for the symptomatic and topical relief associated with painful inflammatory conditions of the muscloskeletal system. Norflex Gel will be available in both a 30 g and 75 g pack.

Norflex Gel can be massaged lightly into the affected area to provide targeted relief between three and six times daily, depending on the severity of the pain1.

Topical, nonsteroidal anti-inflammatory drugs such as Benzydamine Hydrochloride provide effective pain relief in the treatment of acute musculoskeletal conditions, with a lower risk of the systemic adverse events associated with oral NSAIDs1,4.

Patients with traumatic conditions such as sprains, strains, contusions, the after-effects of fractures as well as acute inflammatory conditions such as myalgia and bursitis1,4 will benefit from the triple action effect of Benzydamine Hydrochloride (Norflex Gel), due to its anti-inflammatory, analgesic and local anaesthetic properties3.

Norflex Gel is currently available at leading pharmacies.

DISCLAIMER: This editorial has been commissioned and brought to you by iNova Pharmaceuticals. Content in this editorial is for general information only and is not intended to provide medical or other professional advice.

References:

  1. Norflex® Gel approved package insert, September 2001.
  2. Impact RX. Script Data - January 2018.
  3. South African Medicine Price Registry. Database of Medicine Prices. [Online] 2018 February 12 [cited 2018 February 15]; Available at URL: http://www.mpr.gov.za/PublishedDocuments.aspx#DocCatId=21.
  4. Massey T, et al. Cochrane Database Syst Rev; (6):CD007402. doi:10.1002/14651858.CD007402.pub2.

Subscribe to our mailing list

* indicates required

Would you like to receive our FREE e-newsletter?

* indicates required
Close